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Background: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary
kidney diseases that frequently result in renal failure. In this cross-sectional observational cohort study, we evaluated
urinary angiotensinogen (AGT) as a potential biomarker to assess renal function in ADPKD.
Methods: Urinary AGT was measured in 233 ADPKD patients and its association with estimated glomerular filtration
rate (eGFR) and height-adjusted total kidney volume (htTKV) were evaluated. The localization of AGT and other
renin-angiotensin system (RAS)-related molecules were identified using immunohistochemistry in human ADPKD tissues.
Results: Baseline urinary AGT/Cr was negatively correlated with CKD-EPI eGFR (r2 = 0.162, P < 0.001) and positively
correlated with htTKV (r2 = 0.107, P < 0.001). Both urinary AGT/Cr and plasma renin activity levels were significantly
elevated in hypertensive ADPKD patients. Among hypertensive subjects, urinary AGT/Cr was significantly increased
in the advanced CKD stages (III-V) compared to early CKD stages (I-II) (28.6 ± 60.3 vs. 93.2 ± 139.3 μg/g, P < 0.001).
Immunohistochemical study showed strong expression of AGT along the cyst-lining epithelial cells as well as the
nearby compressed tubular epithelial cells.
Conclusions: Our results suggested that urinary AGT/Cr may be a valuable biomarker for renal damage in ADPKD
since intrarenal ischemic insults induced by cyst growth and subsequent intrarenal RAS activation may play a
potential role in the development of hypertension and renal dysfunction in ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD)
is one of the most common hereditary kidney diseases
with the prevalence of 1 per 1000-4000 [1–3]. Renal fail-
ure is one of the most serious complications in ADPKD.
Since the renal function starts to decline only after renal
parenchyma has been substituted by abundant cysts and
fibrotic tissues, there has been a growing need for* Correspondence: curie@snu.ac.kr
2Research Coordination Center for Rare Diseases, Seoul National University
Hospital, Seoul, South Korea
3Transplantation Research Institute, Seoul National University, Seoul, South
Korea
Full list of author information is available at the end of the article
© 2015 Park et al. This is an Open Access artic
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/discovering novel biomarkers that better reflect the de-
gree of renal damage before renal function declines.
Several biomarkers for renal dysfunction in ADPKD
have been discovered and evaluated [4–9]. We also ob-
served both urinary N-acetyl-β-D-glucosaminidase/
creatinine (NAG/Cr) and β2-microglobulin/creatinine
(β2MG/Cr) were associated with renal dysfunction in
ADPKD [10]. However, previous studies failed to demon-
strate the relationship between biomarker and underlying
renal pathophysiology.
ADPKD patients develop hypertension earlier than the
essential hypertensive patients and it is also well known
that early-onset hypertension is the major predictorle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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angiotensin system (RAS) has been suggested as the
main mechanism in the development of hypertension in
ADPKD since cyst development and growth activate and
accelerate intrarenal RAS far earlier than renal fibrosis
and renal dysfunction. Urinary angiotensinogen (AGT)
has been suggested as a biomarker reflecting the intrare-
nal RAS activity in hypertensive patients [12]. Moreover,
urinary AGT levels were well correlated with renal func-
tion and the degree of albuminuria in a wide range of
chronic kidney disease population [13–16]. Since RAS
activation is closely linked to early-onset hypertension
and subsequent renal damage, this study investigated
1) the association of urinary AGT/Cr to estimated
glomerular filtration rate (eGFR) and height-adjusted
TKV (htTKV), 2) its relationship with hypertensive status,
and 3) tissue expression of AGT and other intrarenal RAS-
related peptides in ADPKD human kidneys.
Methods
Study population
From January 2011 to February 2012, a total of 304
ADPKD patients above 18 years regularly visiting our
ADPKD clinic were enrolled in the study. ADPKD was
clinically diagnosed according to the Unified Criteria for
Ultrasonographic Diagnosis of ADPKD proposed by Pei
et al [17]. Among them, 71 patients were excluded from
the analysis due to following reasons: 34 patients older
than 60 years old, 5 patients on hemodialysis, 4 patients
who received kidney transplantation, 12 patients with
cancer, 8 patients currently on immunosuppressive ther-
apy for the various reasons, 1 patient with previous
unilateral nephrectomy, 2 patients who did not take
computed tomography (CT) exam, 4 patients with
chronic viral hepatitis, and 1 pregnant patient. As a re-
sult, a total of 233 patients were included in an analysis.
Data collection
Upon enrollment, the demographic information and la-
boratory parameters were investigated. Systolic and dia-
stolic blood pressures were measured at every visit and
the number and types of anti-hypertensive medications
were also reviewed. Upon enrollment, blood samples
were withdrawn and serum Cr was measured by Jaffe
method. The eGFR was calculated using chronic kidney
disease epidemiology (CKD-EPI) equation [18, 19].
The chronic kidney disease (CKD) stage was defined
according to the eGFR estimated by CKD-EPI equa-
tion as follows: stage I (>90 mL/min/1.73 m2), stage II
(60-90 mL/min/1.73 m2), stage IIIA (45-60 mL/min/
1.73 m2), stage IIIB (30-45 mL/min/1.73 m2), stage IV
(15-30 mL/min/1.73 m2), and stage V (<15 mL/min/
1.73 m2) [20]. To evaluate systemic RAS activity,
plasma renin activity (PRA) and basal aldosterone weremeasured on resting state. Albumin and Cr were measured
from random urine samples.
Measurement of TKV
Of 233 patients, 200 patients underwent CT within
1 year from their enrollment time points. Thirty-three
patients were excluded from the analysis because they
underwent CT scans apart from urinary biomarker
measurement (>1 year). Among them, 189 patients had
available height information to calculate htTKV (mL/m)
[21]. We have calculated TKV from 3- to 5-mm thick-
ness three-dimensional contrast-enhanced CT of the
kidney and bladder using a multi-detector CT scanner
(Somatom Sensation 16, SIEMENS; Light speed Ultra 8,
GE; Brilliance CT 64, Philips; Somatom Definition,
SIEMENS). The CT examination was performed either
with contrast agent or without depending on patient’s
renal function. In order to acquire contrast images, we
administered contrast material right after pre-contrast
image acquisition and acquire post-contrast images about
17-20 s later when the Hounsfield Unit (HU) at the de-
scending aorta reaches 100HU. The htTKV was defined
as the sum of the left and right renal volumes divided by
height of the patient.
Measurement of urinary AGT
Urine samples were separately collected for the measure-
ment of urinary AGT, mixed with 1 mL of 10 mM Tris
buffer, centrifuged at 3000 g for 10 min, and stored
at -80 °C until measurement. Urinary AGT was mea-
sured by commercial sandwich enzyme-linked immuno-
sorbent assay (ELISA) (Immuno-Biological Laboratories,
Co., Ltd., Gunma, Japan). Urine samples were diluted 10
times before the measurement. To evaluate whether urin-
ary AGT is a better biomarker for renal function in
ADPKD, we also measured urinary NAG and β2MG. The
activity of urinary NAG was measured by a spectrophoto-
metric assay under a 340-nm wavelength using a TBA 200
FR biochemical analyzer (Toshiba, Tokyo, Japan) [22]. The
urinary excretion level of β2MG was measured using a
radioimmunoassay kit (Beckman Coulter, Prague, Czech
Republic) [23]. To compensate for the production of con-
centrated or dilute urine samples, the urinary biomarker
levels were expressed based on urinary Cr content.
Immunohistochemistry
One normal kidney specimen and two polycystic kidney
specimens were collected from radical nephrectomized
kidneys (Table 1). Each kidney specimen was fixed in 4 %
paraformaldehyde (PFA) for 24 h and paraffin embedded.
The 4-μm sections were prepared for immunohistochem-
istry as described before [24]. Antigen retrieval was per-
formed with Tris-EDTA buffer, pH9.0, at 100 °C for
15 min. The slides were rinsed three times with PBS,
Table 1 Clinical characteristics of the nephrectomized patients
Normal control Case I Case II
(Normotensive) (PKD-CKD) (PKD-ESRD)
Gender/Age (yr) M / 38 F / 48 M / 61
Diagnosis Renal cell carcinoma Renal cell carcinoma, ADPKD ADPKD
Creatinine (mg/dL) 1.1 0.98 5.4
Hypertension duration (yr) - 14 12
Hypertension medication 0 Valsartan 160 mg, Tenormin 12.5 mg Candesartan 8 mg, Amlodipine 10 mg
Systolic/diastolic blood pressure (mmHg) 120 / 70 134 / 91 137 / 85
ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; ESRD, end-stage renal disease
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temperature to block endogenous peroxidase. The slides
were rinsed three times with PBS and then blocker with
universal blocking buffer. The primary antibodies were
added at the dilution indicated in Table 2. Slides were in-
cubated either for 1 h at room temperature or overnight
at 4 °C, followed by the addition of the secondary anti-
bodies. Sections were stained with DAB substrate and
counterstained with hematoxylin, and viewed under a
Leica microscope.Statistical analyses
Statistical analyses were performed using SPSS, version
19.0 (SPSS Inc., www.spss.com). The variables that did
not follow normal distribution were log-transformed be-
fore analysis. To investigate whether urinary biomarkers
were correlated with either eGFR or htTKV, linear
regression analyses were performed. To adjust for poten-
tial confounders, multiple regression analysis was per-
formed. We also performed independent t-test and the
analysis of variance (ANOVA) test to compare continu-
ous variables between groups. The P-value < 0.05 was
considered statistically significant.Ethics statement
This study was approved by the Institutional Review
Board of Seoul National University Hospital (H-0901-
046-269). The procedures for the use of the human kidney
specimens were approved by Seoul National University
Hospital Institutional Review Board (H-0701-033-195). AllTable 2 Primary antibodies used in the immunohistochemistry
Target Molecule Immunogen Host
AGT Human AGT Mouse
AngII Human angiotensin II Rabbit
Ang-(1-7) Rat angiotensin (1-7) Rabbit
ACE Human ACE Mouse
ACE2 NS0-derived rhACE-2 ectodomain Goat
Chymase Human chymase (skin) Mouse
ACE angiotensin converting enzyme, ACE2 angiotensin converting enzyme 2, AngII angiparticipants provided written informed consent before the
study in accordance to the Declaration of Helsinki.
Results
Clinical characteristics of participants
A total of 233 ADPKD patients were selected for this
study. Baseline clinical characteristics are summarized in
Table 3. The mean age was 43.3 ± 9.7 years and had
slight female predominance (54.1 %). The majority of
them were either diagnosed with hypertension or on
blood pressure lowering therapy (n = 217, 93.1 %), and
153 patients were taking angiotensin converting enzyme
inhibitor (ACEi) and/or angiotensin receptor blocker
(ARB). Mean serum Cr and eGFR were 1.1 ± 0.5 mg/dL
and 80.5 ± 27.1 mL/min/1.73 m2, respectively. The me-
dian value of urinary AGT/Cr was 13.7 (Interquartile
range, IQR 7.5 – 35.1) μg/g. The CT scan was taken in
189 subjects. Measured htTKV at baseline was 705 mL/m
(Min. 119, Max. 3436) and the mean time gap be-
tween urinary biomarker measurement and CT scan
was 4.7 ± 4.0 months.
Urinary AGT was correlated with eGFR and htTKV
To evaluate the association between each urinary bio-
marker and renal functional and structural markers, a
linear regression analyses were performed. Urinary AGT,
NAG, and β2MG were compared with eGFR, serum Cr,
and htTKV. Urinary AGT/Cr was negatively correlated
with eGFR (r2 = 0.162, P < 0.001)(Fig. 1). When compared
with urinary NAG/Cr and β2MG/Cr, urinary AGT/Cr
showed the best correlation with eGFR demonstrating theType Source Dilution
Monoclonal R&D Systems 1:600
Polyclonal affinity purified Novus Biologicals 1:100
Polyclonal affinity purified Alomone Labs 1:100
Monoclonal Abcam 1:50
Polyclonal affinity purified R&D Systems 1:10
Polyclonal affinity purified Chemicon International 1:500
otensin II, Ang-(1-7) angiotensin (1-7), AGT angiotensinogen
Table 3 Baseline clinical characteristics of participants
Parameters Patients (N = 233) Patients with htTKV (N = 189) Patients without htTKV (N = 44) P-value
Age (yr) 43.3 ± 9.7 43.8 ± 9.3 41.2 ± 11.3 0.198
Female 126 (54.1 %) 99 (52.4 %) 27 (61.4 %) 0.316
Age at diagnosis (yr) 34.7 ± 9.2 35.2 ± 9.2 32.2 ± 8.9 0.114
Hypertension 217 (93.1 %) 147 (77.8 %) 29 (65.9 %) 0.119
Duration of hypertension (yr) 8.6 ± 6.0 8.6 ± 5.9 8.6 ± 6.6 0.67
Systolic BP (mmHg) 129.8 ± 13.5 130.0 ± 13.8 129.0 ± 12.6 0.404
Diastolic BP (mmHg) 80.0 ± 9.9 80.5 ± 10.0 78.1 ± 9.4 0.049
Number of BP medication 1 (Min. 0, Max. 7) 1 (Min. 0, Max. 7) 1 (Min. 0, Max. 4) 0.686
ARB or ACEi medication (%) 153 (65.7 %) 122 (64.6 %) 30 (68.2 %) 0.825
HtTKV (mL/m) - 705 (Min 119, Max. 3436) - -
Time gap between enrollment and CT volumetry (mo) - 4.7 ± 4.0 - -
Hemoglobin (g/dL) 13.4 ± 1.5 13.4 ± 1.6 13.3 ± 1.3 0.592
Creatinine (mg/dL) 1.1 ± 0.5 1.2 ± 0.5 0.9 ± 0.3 0.003
CKD-EPI eGFR (mL/min/1.73 m2) 80.5 ± 27.1 77.9 ± 27.1 91.7 ± 24.9 0.002
Random urine microalbumin-to-creatinine ratio (mg/g) 21.0 (9.0–64.5) 23.0 (11.0–66.5) 15.0 (6.0–43.0) 0.076
PRA (ng/mL/hr) 3.6 (1.4–8.2) 3.9 (1.4–9.0) 3.0 (0.9–5.3) 0.067
Plasma aldosterone (ng/dL) 15.8 (11.7–21.6) 14.9 (11.4–21.1) 18.3 (12.3–23.7) 0.232
Urinary AGT/Cr (μg/g) 13.7 (7.5–35.1) 14.9 (7.8–36.0) 13.1 (6.2–30.8) 0.289
Urinary NAG/Cr (IU/g) 3.9 (2.7–5.9) 4.0 (2.9–5.9) 3.5 (2.3–6.1) 0.206
Urinary β2MG/Cr (μg/g) 310.6 (214.3–560.0) 305.8 (215.9–552.9) 329.1 (206.3–654.6) 0.871
Data are expressed as numbers (percentages), mean ± SD, or median (Interquartile range). HtTKV was measured in 189 patients with available height and CT volumetry.
ACEi angiotensin converting enzyme inhibitor, AGT angiotensinogen, ARB angiotensin receptor blocker, β2MG β2-microglobulin, BP blood pressure, CKD-EPI eGFR chronic
kidney disease epidemiology estimated glomerular filtration rate, HtTKV height-adjusted total kidney volume, PRA plasma renin activity, NAG N-acetyl-β-D-glucosaminidase.
Urinary concentrations of biomarkers were log-transformed to fulfill the requirement of normal distribution of residuals
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0.111 vs. 0.138, P < 0.001) (Additional file 1: Figure S1).
Furthermore, when we performed ANOVA among CKD
stage groups, the mean values of urinary AGT/Cr in-
creased according to CKD stages (CKD stage I-II (n = 186),Fig. 1 Linear Regression Analysis Between Urinary Angiotensinogen/Creatin
(AGT/Cr) showed negative correlation with eGFR (r2 = 0.162, P < 0.001) and27.8 ± 58.5 μg/g; CKD stage IIIA (n = 22), 56.0 ± 61.1 μg/g;
CKD stage IIIB (n = 15), 89.0 ± 89.5 μg/g; CKD stage IV-V
(n = 9), 95.3 ± 108.9 μg/g) (Fig. 2).
Among 189 patients with available htTKV measurement,
urinary AGT/Cr also demonstrated a better correlationine Ratio, eGFR, and htTKV. Urinary angiotensinogen/creatinine ration
positive correlation with htTKV (r2 = 0.107, P < 0.001)
Fig. 2 Urinary AGT/Cr According to CKD Stages and htTKV. The urinary AGT/Cr value was significantly increased as CKD stages progressed
(CKD stage 1-2 (n = 186), 27.8 ± 58.5 μg/g; CKD stage 3A (n = 22), 56.0 ± 61.1 μg/g; CKD stage 3B (n = 15), 89.0 ± 89.5 μg/g; CKD stage 4-5
(n = 9), 95.3 ± 108.9 μg/g). In addition, the subjects with larger htTKV (≥750 mL/m) demonstrated greater urinary AGT/Cr level (50.9 ± 76.7 vs.
23.5 ± 48.2 μg/g, P = 0.003). ** Each value showed statistically significant difference (P < 0.05) compared to the reference value (CKD stage I-II,
HtTKV < 750 mL/m). AGT, angiotensinogen; CKD, chronic kidney disease; Cr, creatinine; htTKV, height-adjusted total kidney volume
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and β2MG/Cr (r2 = 0.089 and r2 = 0.08, P < 0.001)
(Additional file 1: Figure S1). The patients with larger
htTKV > 750 mL/m (n = 90) showed greater urinary AGT/
Cr (50.9 ± 76.7 μg/g) compared with those with smaller
kidneys < 750 mL/m (23.5 ± 48.2 μg/g, P = 0.003) (Fig. 2).
These results indicated that urinary AGT/Cr shows a good
correlation with both concurrent eGFR and htTKV.Fig. 3 Urinary AGT/Cr and PRA Levels According to CKD Stages and Hyper
AGT/Cr and compared with PRA level, a marker of systemic RAS activation.
compared to normotensive subjects (P > 0.05). Among hypertensive subjec
stages (III-V, gray bar) compared to early CKD stages (I-II, white bar)(28.6 ± 6
statistically different between CKD stage groups. AGT, angiotensinogen; CKUrinary AGT demonstrated better association with CKD
stages compared to PRA in hypertensive ADPKD patients
Since RAS activation is a major cause of hypertension
in ADPKD patients, urinary AGT/Cr and PRA levels
were compared among normotensive and hypertensive
groups. As shown in Fig. 3, both urinary AGT/Cr and
PRA were tended to be higher in hypertensive subjects
compared to normotensive subjects (P > 0.05). Amongtension. As a marker of intrarenal RAS activation, we measured urinary
Both urinary AGT/Cr and PRA were elevated in hypertensive subjects
ts, urinary AGT/Cr was significantly increased in the advanced CKD
0.3 vs. 93.2 ± 139.3 μg/g, P < 0.001). In contrast, PRA levels were not
D, chronic kidney disease; Cr, creatinine; PRA, plasma renin activity
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increased in the advanced CKD stages (III-V) compared
to early CKD stages (I-II) (28.6 ± 60.3 vs. 93.2 ±
139.3 μg/g, P < 0.001). This remained statistically sig-
nificant when we compared urinary AGT/Cr among
the subgroup population who were not taking RAS
blocker medications (29.9 ± 54.0 vs. 106.7 ± 217.7 μg/g,
P = 0.009, data not shown). On the other hand, PRA
could not differentiate those with decreased renal func-
tion from those with normal renal function (7.5 ± 8.7 vs.
7.4 ± 10.2 ng/mL/hr, P = 0.928). In concordance to previous
studies, our results suggest that local RAS (represented by
urinary AGT/Cr) as well as systemic RAS (represented
by PRA) are activated in hypertensive patients. However,
urinary AGT/Cr showed better association with CKD
stages among hypertensive subjects compared to PRA.
Meanwhile, RAS blockers, ACEi and/or ARB, did not
affect either urinary AGT/Cr levels or PRA/aldosterone
levels (Additional file 1: Figure S2).
Urinary AGT was not an independent risk factor for
reduced eGFR
To evaluate clinical variables associated with eGFR, we
performed a linear regression analysis. Age, gender, and
hypertension were evaluated as demographic variables.
The eGFR at the initial hospital visit, plasma hemoglobin,
serum uric acid, htTKV, random urine albumin to Cr ra-
tio, urinary AGT/Cr were included as laboratory parame-
ters. In univariate analysis, higher urinary AGT/Cr was
associated with reduced eGFR as well as old age, hyperten-
sion, low initial eGFR, low plasma hemoglobin, high
serum uric acid, large htTKV, and microalbuminuria
(Table 4). Since the association between urinary AGT/Cr
and eGFR may be confounded by other clinical variables,
multivariate regression analyses were performed as the
next step. The stepwise selection method was used toTable 4 Linear regression analysis for risk factors for decreased estim
Parameters Univariable
B (95 % CI)
Age (yr) -1.14 (-1.3 to -0.9)
Gender 1.97 (-4.4 to 8.3)
Hypertension -21.1 (-28.1 to -14.1)
Initial eGFR (mL/min/1.73 m2) 0.67 (0.6 to 0.7)
Hemoglobin (g/dL) 6.86 (5.1 to 8.6)
Uric acid (mg/dL) -8.84 (-10.7 to -6.95)
HtTKV (mL/m) -18.8 (-22.6 to -15.0)
Albumin/Cr (mg/g) -11.2 (-13.3 to -9.12)
Urinary AGT/Cr (μg/g) -9.5 (-11.8 to -7.19)
In multivariate analysis, data were adjusted for age, hypertension, initial eGFR, plasma h
urinary AGT/Cr by stepwise selection method. HtTKV, albumin/Cr, and AGT/Cr were log
angiotensinogen, Cr creatinine, eGFR estimated glomerular filtration rate, htTKV height-adefine independent factors. Age, hypertension, initial
eGFR, plasma hemoglobin, serum uric acid, htTKV, ran-
dom urine albumin to Cr ratio, urinary AGT/Cr were in-
cluded in the final model. Old age, low initial eGFR, low
plasma hemoglobin, high serum uric acid, and large
htTKV were the independent factors associated with re-
duced eGFR. However, urinary AGT/Cr was not an inde-
pendent factor associated with reduced eGFR.
AGT was overexpressed in cyst-lining epithelial cells and
proximal tubules of ADPKD compared to normal kidneys
In order to investigate the origin of AGT expression in
polycystic kidneys, immunohistochemistry was per-
formed using normal and polycystic kidney tissues. In
the normal kidney, AGT was not expressed in any of
proximal tubules, glomeruli, or vessels. On the other
hand, in case I (PKD-CKD), AGT was strongly expressed
in proximal tubules and cyst-lining epithelial cells
(Fig. 4). Of note, the staining intensity of AGT was
greater in the proximal tubules compressed by nearby
cysts. In case II, PKD-end-stage renal disease (ESRD),
AGT was also expressed in the proximal tubules; how-
ever, its intensity was slightly reduced than that of case I.
Nevertheless, strong expression of AGT was also noted at
cyst-lining epithelial cells in case II.
Other intrarenal RAS components were highly expressed
in ADPKD
Expression levels of other intrarenal RAS components
such as AngII, Ang-(1-7), ACE, ACE2, and chymase
were investigated using immunohistochemical staining
(Fig. 4, Table 5). Immunohistochemitry results of case I
demonstrated that all other intrarenal RAS components
including AngII, Ang-(1-7), ACE2 and chymase but ACE
expression were augmented in the polycystic kidneys
compared to the normal kidney. The AngII expressionated glomerular filtration rate
Multivariable
P value B (95 % CI) P value
<0.001 -0.5 (-0.66 to -0.33) <0.001
0.54
<0.001
<0.001 0.3 (0.22 to 0.38) <0.001
<0.001 2.91 (1.61 to 4.21) <0.001
<0.001 -4.22 (-5.66 to -2.78) <0.001
<0.001 -5.6 (-8.57 to -2.63) <0.001
<0.001 -3.31 (-4.99 to -1.64) <0.001
<0.001 -1.63 (-3.74 to 0.48) 0.1
emoglobin, serum uric acid, htTKV, random urine albumin-to-creatinine ratio, and
-transformed to fulfill the requirement of normal distribution of residuals. AGT
djusted total kidney volume
Fig. 4 Immunohistochemistry of Intrarenal RAS Components in Polycystic Kidneys. Immunohistochemistry was performed to evaluate the
expression levels of intrarenal RAS components in the polycystic kidneys (PKD-CKD and PKD-ESRD) compared to normal control kidneys. AGT was
highly expressed in the proximal tubules and cyst-lining epithelial cells in polycystic kidneys whereas normal kidney did not express AGT in either
glomeruli or tubules. Other intrarenal RAS components (AngII, Ang-(1-7), ACE2, and chymase) were highly expressed in polycystic kidneys compared to
the normal kidney. However, the expression level of ACE was lower in the polycystic kidneys compared to the normal control. Magnification x400. ACE,
angiotensin converting enzyme; ACE2, angiotensin converting enzyme 2; AGT, angiotensinogen; AngII, angiotensin II; Ang-(1-7), Angiotensin (1-7); CKD,
chronic kidney disease; ESRD, end-stage renal disease; PKD, polycystic kidney disease; RAS, renin-angiotensin system
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bules. The Ang-(1-7) expression was markedly increased
in proximal and distal tubules and glomeruli. The ACE2
expression was markedly increased in the proximal
tubular cells of polycystic kidneys. However, the ACE2
expression level in the distal tubules was similar to thatTable 5 Tissue expression of intrarenal renin-angiotensin-aldoste
normal kidney
AGT AngII
Normal PT ± +
DT - +
Case I (ADPKD-CKD) C ++(diffuse) ++
PT +++(diffuse) ++
DT - ++
Case II (ADPKD-ESRD) C ++(patchy) ±
PT +++(patchy) ±
DT - ±
Normal kidney was obtained from 38-year-old male who underwent nephrectomy for
polycystic kidney tissues were obtained from two patients. One patient underwent ne
kidney tissue was obtained from end-stage renal disease patient who was preparing t
enzyme 2, AGT angiotensinogen, AngII angiotensin II, Ang-(1-7) angiotensin (1-7), C cyst-lini
kidney disease stage, ADPKD-ESRD polycystic kidney disease – end-stage renal disease stagof normal kidney. Of note, the expression level of chy-
mase, an alternative enzyme which converts AngI to
AngII, was moderately increased in both proximal and
distal tubules. Meanwhile, ACE expression levels were
decreased in polycystic kidney tissue compared to the
stain intensity in normal kidney tissue. Immunochemistryrone system components in polycystic kidneys compared to
Ang-(1-7) ACE ACE2 Chymase
++ +++ ++ +
+ - ++ +
++ - ± -
+++ + ++++ +++
+++ - ++ ++
+++ - + +
+++ ± ++++ +++
+++ - ++ ++
renal cell carcinoma. His sCr level was 1.1 mg/dL at the time of operation. The
phrectomy for renal cell carcinoma and her sCr level was 0.98 mg/dL. The other
ransplantation. ACE angiotensin-converting enzyme, ACE2 angiotensin-converting
ng epithelial cells, DT distal tubules, ADPKD-CKD polycystic kidney disease – chronic
e, PT Proximal tubule
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sion to case I, but cyst-lining epithelial cells were posi-
tively stained especially for Ang-(1-7). The staining
pattern of AngII, ACE2 and chymase in polycystic kidney
tissue was rather patchy with less staining intensity com-
pared to those in case I.
Discussion
AGT is a 52- to 64- kD peptide molecule that has a lim-
ited glomerular permeability and tubular degradation.
Because of these properties, urinary AGT has been stud-
ied as a marker for the intrarenal RAS activity among
other RAS related proteins [25]. As a novel biomarker
that reflects intrarenal RAS activity, urinary AGT has
been reported to be associated with hypertension, pro-
teinuria, and renal dysfunction [12, 13, 25]. It has
recently been recognized as an important urinary bio-
marker for hypertension in ADPKD patients [26].
Our study is the largest study to demonstrate urinary
AGT/Cr as a useful clinical parameter associated with
renal dysfunction and underlying pathophysiology. In
this study, urinary AGT/Cr demonstrated a better asso-
ciation with concurrent eGFR, htTKV, and hypertension
compared to other biomarkers including urinary NAG/
Cr and β2MG/Cr. In addition, our immunohistochemi-
cal staining results showed that most of RAS compo-
nents including AGT were highly expressed in the
polycystic kidney tissues compared to normal kidney.
These results suggest that intrarenal RAS activation may
play an important role in blood pressure elevation and
renal dysfunction. Indeed, high blood pressure often
manifests far earlier than cyst growth and replacement
of renal parenchyma. It suggests that not only mechan-
ical compression by cysts but also paracrine hormonal
action will be crucial for developing hypertension in
ADPKD.
In our study, urinary AGT/Cr was well correlated with
concurrent eGFR and htTKV even in the early CKD
stages. In the previous study, urinary AGT/Cr measured
from healthy volunteers ranged from 5.0 to 30.0 μg/g
(Additional file 1: Table S1) [27]. In our study, urinary
AGT/Cr levels in ADPKD patients began to increase
from as early as CKD stage I-II (27.8 ± 58.5 μg/g), show-
ing higher value than those in hypertensive patients
without RAS blocker usage [12]. It suggests that urinary
AGT/Cr may reflect early stage renal damage well before
renal functional (serum Cr or eGFR) and structural
markers (htTKV) change. In addition, the fact that urin-
ary AGT/Cr was higher in the patients with hyperten-
sion compared to normotensive patients clearly show
that urinary AGT/Cr can be a meaningful biomarker
that reflects underlying pathophysiology of ADPKD.
However, in multivariate analysis, the association be-
tween urinary AGT/Cr and eGFR was disappeared afteradjustment with other clinical variables including age,
gender, hypertension, and initial eGFR. Like many other
biomarkers for ADPKD [8], independent effect of urin-
ary AGT/Cr seemed to be reduced by the impact of
initial eGFR, which may pose strong impact on the sub-
sequent eGFR. In addition, various confounding factors
may affect urinary AGT/Cr levels such as medication,
ACE gene polymorphisms and diet.
In this study, the use of ACE inhibitors and/or ARBs
did not result in decreased urinary AGT/Cr. It is hard to
directly compare this with previous studies because most
of previous studies were performed in the prospective
trial design. However, there are several possible explana-
tions. First, the information about the duration of RAS
blocker prescription was not collected and analyzed.
This is important because intrarenal RAS activity seems
to rebound sometime after using RAS blockers. Jang
et al. clearly showed this in their previous study that
urinary AGT/Cr was increased again after 3 months of
RAS blocker medication [28]. Second, there is a possibil-
ity that inadequate amount of RAS blockers was used
that could not suppress intrarenal AngII activity.
However, our immunohistochemical study suggests
AGT may be produced and secreted vigorously in the
early CKD stages. In concordance to previous study re-
sults, AGT was highly expressed in proximal tubular
epithelial cells and cyst-lining cells of ADPKD [24].
Notably, the expression level of AGT was much stronger
in case I (PKD-CKD, eGFR 69 mL/min/1.73 m2 with
hypertension) than that in case II (PKD-ESRD, eGFR
11 mL/min/1.73 m2 with hypertension, pre-dialysis) sug-
gesting that urinary AGT/Cr may be more useful in the
early stage of renal disease. Previous studies support our
results, clearly showing that all the intrarenal RAS com-
ponents are highly expressed in the proximal tubules in
the pathologic condition [24, 28, 29]. Proximal tubular
cells can actively produce AngII and also secrete AGT
into the urine [30]. Intraluminal AGT may be converted
in the distal tubules to AngII, which may lead to induc-
tion of sodium channels and aldosterone production to
elevate blood pressure [31].
Unravelling the mechanisms involving intrarenal RAS
activation in ADPKD is beyond the scope of this study
since this study aims to investigate the clinical usefulness
of urinary AGT/Cr as a biomarker of renal insufficiency.
However, it is worthy to note that the expression levels
of the counterpart molecules, ACE2 and Ang-(1-7), were
also elevated in the polycystic kidneys. Two possible ex-
planations can be given. First, since the subjects were
taking ARB to block the action of AngII, the feedback
mechanism would increase the production of upstream
molecules, AGT and AngII. Ang II is then further con-
verted to Ang (1-7) directly by ACE. Another possible
mechanism is that the dose of RAS blocker was
Park et al. BMC Nephrology  (2015) 16:86 Page 9 of 10insufficient to decrease intrarenal RAS activity hence the
counterpart pathway was activated to compensate the
deleterious effects of AngII. The functional effect of
increased ACE2 and Ang-(1-7) should be demonstrated
in the further study.
The expression of ACE was universally decreased in
ADPKD tissue compared to normal control. Previous
study suggested that AngII production in organ or tissue
may rely more on chymase rather than ACE in patho-
logic conditions [32]. The other study also demonstrated
that AngII activity in heart, aorta, and lung under the
hypertensive condition was more dependent on chymase
activity rather than ACE activity [33]. Therefore, in
pathologic conditions, chymase activity may overtake the
role of ACE in the production of AngII.
This study has several limitations. This is a single-
center, cross-sectional study that included only Korean pa-
tients. Second, we failed to show independent association
between urinary AGT/Cr and eGFR. Third, patients in
advanced CKD stages were largely excluded. Lastly, TKV
was measured using a modified ellipsoid method from CT
images. The modified ellipsoid method was originally de-
veloped to measure kidney volumes from ultrasonographic
images [34]. In addition, most previous studies measured
TKV by computer-based volumetry using magnetic reson-
ance imaging (MRI). Further validation studies are war-
ranted to use this method in CT volumetry.
Conclusions
We found that high urinary level of AGT/Cr was associ-
ated with lower eGFR, larger htTKV, and hypertension.
Immunohistochemical results demonstrated the possible
link between ischemic insult by cyst growth and subse-
quent activation of intrarenal RAS in the progression of
ADPKD. Further long-term studies should reveal the
usefulness of urinary AGT/Cr in the prediction of faster
renal function deterioration.Additional file
Additional file 1: Figure S1. Association Between Urinary Biomarker
Concentration, eGFR, serum Cr, and htTKV. All patients measured urinary
angiotensinogen (AGT), N-acetyl- β-D-glucosaminidase (NAG), and
β2-microglobulin (β2MG). Urinary biomarker concentration was
expressed based on urinary Cr contents. The concentration of each
urinary biomarker, serum Cr, and htTKV were log-transformed before
analysis. Among them, 189 patients had available htTKV measurement
within 1 year of enrollment. Among other biomarkers, urinary AGT/Cr
showed a better association with eGFR (r2 = 0.162, P < 0.001) and htTKV
(r2 = 0.107, P < 0.001). Figure S2. Urinary AGT/Cr, PRA, and Plasma
Aldosterone Levels According to RAS Blocker Usage. Urinary AGT/Cr was
not statistically different between patients with RAS blocker usage
(n = 153, 39.5 ± 70.2 μg/g) and those without RAS blocker usage (n = 64,
47.9 ± 117.6 μg/g, P = 0.595). In addition, PRA and plasma aldosterone,
markers of systemic RAS activation, did not differ between groups
(P >0.05). Table S1. Comparison of Urinary AGT/Cr Levels among
Different Studies.Abbreviations
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